ASCO GI 2023 | DKN-01 with bevacizumab and chemotherapy in advanced CRC
Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, provides an overview of the trial design and rationale of the Phase II DeFianCe study (NCT05480306) of second-line DKN-01, an anti-DKK-1 monoclonal antibody, in combination with standard of care bevacizumab, FOLFIRI, and FOLFOX in patients with second-line colorectal cancer (CRC). Patients received either received the investigational therapy or bevacizumab and chemotherapy alone, where the primary endpoint was progression-free survival. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
The DeFianCe trial is a second line trial with colon cancer adding a DKK-1 inhibitor called DKN-01 to standard of care chemotherapy and second line colon cancer. It blocks a protein in DKN-01, which is important in a subset of colon cancer with high wnt signaling activity. So the trial will look at the combination of that drug with chemotherapy compared to chemotherapy alone in second line metastatic colon cancer...
The DeFianCe trial is a second line trial with colon cancer adding a DKK-1 inhibitor called DKN-01 to standard of care chemotherapy and second line colon cancer. It blocks a protein in DKN-01, which is important in a subset of colon cancer with high wnt signaling activity. So the trial will look at the combination of that drug with chemotherapy compared to chemotherapy alone in second line metastatic colon cancer.
Read more...
